Effect Of PF-06305591 On Capsaicin And Capsaicin/Heat-Induced Neurogenic Flare

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Healthy
Interventions
DRUG

PF-06305591

150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.

OTHER

Capsaicin challenge

110 mg capsaicin cream (Axsain®) will be applied topically at each visit.

DRUG

Placebo

Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.

OTHER

Capsaicin challenge

110 mg capsaicin cream (Axsain®) will be applied topically at each visit.

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01797796 - Effect Of PF-06305591 On Capsaicin And Capsaicin/Heat-Induced Neurogenic Flare | Biotech Hunter | Biotech Hunter